EdgarLookup

ORACLE CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that ORACLE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
21.7%
Profit Margin
Net income ÷ revenue
7.4%
Return on Assets
Net income ÷ assets
+8.4%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $57.40B Jun 18, 2025
FY2025 May 31, 2024 $52.96B Jun 18, 2025
FY2025 May 31, 2023 $49.95B Jun 18, 2025
FY2022 May 31, 2022 $42.44B Jun 21, 2022
FY2022 May 31, 2021 $40.48B Jun 21, 2022
FY2022 May 31, 2020 $39.07B Jun 21, 2022
FY2021 May 31, 2019 $39.51B Jun 21, 2021
FY2020 May 31, 2018 $39.38B Jun 22, 2020
FY2019 May 31, 2017 $37.79B Jun 21, 2019
FY2018 May 31, 2016 $37.05B Jun 22, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $57.40B Jun 18, 2025
FY2025 May 31, 2024 $52.96B Jun 18, 2025
FY2025 May 31, 2023 $49.95B Jun 18, 2025
FY2024 May 31, 2022 $42.44B Jun 20, 2024
FY2023 May 31, 2021 $40.48B Jun 20, 2023
FY2022 May 31, 2020 $39.07B Jun 21, 2022
FY2021 May 31, 2019 $39.51B Jun 21, 2021
FY2020 May 31, 2018 $39.38B Jun 22, 2020
FY2019 May 31, 2017 $37.79B Jun 21, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2011 May 31, 2011 $6.94B Jun 28, 2011
FY2010 May 31, 2010 $2.29B Jul 1, 2010
FY2010 May 31, 2009 $0 Jul 1, 2010
FY2010 May 31, 2008 $0 Jul 1, 2010

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2018 May 31, 2018 $24.29B Jun 22, 2018
FY2018 May 31, 2017 $23.02B Jun 22, 2018
FY2018 May 31, 2016 $22.41B Jun 22, 2018
FY2017 May 31, 2015 $23.71B Jun 27, 2017

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $12.44B Jun 18, 2025
FY2025 May 31, 2024 $10.47B Jun 18, 2025
FY2025 May 31, 2023 $8.50B Jun 18, 2025
FY2024 May 31, 2022 $6.72B Jun 20, 2024
FY2023 May 31, 2021 $13.75B Jun 20, 2023
FY2022 May 31, 2020 $10.14B Jun 21, 2022
FY2021 May 31, 2019 $11.08B Jun 21, 2021
FY2020 May 31, 2018 $3.59B Jun 22, 2020
FY2019 May 31, 2017 $9.45B Jun 21, 2019
FY2018 May 31, 2016 $8.90B Jun 22, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $17.68B Jun 18, 2025
FY2025 May 31, 2024 $15.35B Jun 18, 2025
FY2025 May 31, 2023 $13.09B Jun 18, 2025
FY2024 May 31, 2022 $10.93B Jun 20, 2024
FY2023 May 31, 2021 $15.21B Jun 20, 2023
FY2022 May 31, 2020 $13.90B Jun 21, 2022
FY2021 May 31, 2019 $13.54B Jun 21, 2021
FY2020 May 31, 2018 $13.26B Jun 22, 2020
FY2019 May 31, 2017 $12.91B Jun 21, 2019
FY2018 May 31, 2016 $12.60B Jun 22, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $9.86B Jun 18, 2025
FY2025 May 31, 2024 $8.92B Jun 18, 2025
FY2025 May 31, 2023 $8.62B Jun 18, 2025
FY2024 May 31, 2022 $7.22B Jun 20, 2024
FY2023 May 31, 2021 $6.53B Jun 20, 2023
FY2022 May 31, 2020 $6.07B Jun 21, 2022
FY2021 May 31, 2019 $6.03B Jun 21, 2021
FY2020 May 31, 2018 $6.08B Jun 22, 2020
FY2019 May 31, 2017 $6.15B Jun 21, 2019
FY2018 May 31, 2016 $5.79B Jun 22, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $20.82B Jun 18, 2025
FY2025 May 31, 2024 $18.67B Jun 18, 2025
FY2025 May 31, 2023 $17.17B Jun 18, 2025
FY2024 May 31, 2022 $9.54B Jun 20, 2024
FY2023 May 31, 2021 $15.89B Jun 20, 2023
FY2022 May 31, 2020 $13.14B Jun 21, 2022
FY2021 May 31, 2019 $14.55B Jun 21, 2021
FY2020 May 31, 2018 $15.39B Jun 22, 2020
FY2019 May 31, 2017 $14.13B Jun 21, 2019
FY2018 May 31, 2016 $13.69B Jun 22, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $21.22B Jun 18, 2025
FY2025 May 31, 2024 $6.87B Jun 18, 2025
FY2025 May 31, 2023 $8.70B Jun 18, 2025
FY2024 May 31, 2022 $4.51B Jun 20, 2024
FY2023 May 31, 2021 $2.14B Jun 20, 2023
FY2022 May 31, 2020 $1.56B Jun 21, 2022
FY2021 May 31, 2019 $1.66B Jun 21, 2021
FY2020 May 31, 2018 $1.74B Jun 22, 2020
FY2019 May 31, 2017 $2.02B Jun 21, 2019
FY2018 May 31, 2016 $1.19B Jun 22, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $168.36B Jun 18, 2025
FY2025 May 31, 2024 $140.98B Jun 18, 2025
FY2024 May 31, 2023 $134.38B Jun 20, 2024
FY2023 May 31, 2022 $109.30B Jun 20, 2023
FY2022 May 31, 2021 $131.11B Jun 21, 2022
FY2021 May 31, 2020 $115.44B Jun 21, 2021
FY2020 May 31, 2019 $108.71B Jun 22, 2020
FY2019 May 31, 2018 $137.85B Jun 21, 2019
FY2018 May 31, 2017 $134.99B Jun 22, 2018
FY2017 May 31, 2016 $112.18B Jun 27, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $20.45B Jun 18, 2025
FY2025 May 31, 2024 $8.70B Jun 18, 2025
FY2024 May 31, 2023 $1.07B Jun 20, 2024
FY2023 May 31, 2022 ($6.22B) Jun 20, 2023
FY2022 May 31, 2021 $5.24B Jun 21, 2022
FY2021 May 31, 2020 $12.07B Jun 21, 2021
FY2020 May 31, 2019 $21.79B Jun 22, 2020
FY2019 May 31, 2018 $46.37B Jun 21, 2019
FY2018 May 31, 2017 $53.86B Jun 22, 2018
FY2017 May 31, 2016 $47.29B Jun 27, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $62.21B Jun 18, 2025
FY2025 May 31, 2024 $62.23B Jun 18, 2025
FY2025 May 31, 2023 $62.26B Jun 18, 2025
FY2024 May 31, 2022 $43.81B Jun 20, 2024
FY2023 May 31, 2021 $43.94B Jun 20, 2023
FY2022 May 31, 2020 $43.77B Jun 21, 2022
FY2021 May 31, 2019 $43.78B Jun 21, 2021
FY2020 May 31, 2018 $43.76B Jun 22, 2020
FY2019 May 31, 2017 $43.05B Jun 21, 2019
FY2018 May 31, 2016 $34.59B Jun 22, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 ($15.48B) Jun 18, 2025
FY2025 May 31, 2024 ($22.63B) Jun 18, 2025
FY2024 May 31, 2023 ($27.62B) Jun 20, 2024
FY2023 May 31, 2022 ($31.34B) Jun 20, 2023
FY2022 May 31, 2021 ($20.12B) Jun 21, 2022
FY2021 May 31, 2020 ($12.70B) Jun 21, 2021
FY2020 May 31, 2019 ($3.50B) Jun 22, 2020
FY2019 May 31, 2018 $19.11B Jun 21, 2019
FY2018 May 31, 2017 $27.60B Jun 22, 2018
FY2017 May 31, 2016 $23.89B Jun 27, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $10.79B Jun 18, 2025
FY2025 May 31, 2024 $10.45B Jun 18, 2025
FY2024 May 31, 2023 $9.77B Jun 20, 2024
FY2023 May 31, 2022 $21.38B Jun 20, 2023
FY2022 May 31, 2021 $30.10B Jun 21, 2022
FY2021 May 31, 2020 $37.24B Jun 21, 2021
FY2020 May 31, 2019 $20.51B Jun 22, 2020
FY2019 May 31, 2018 $21.62B Jun 21, 2019
FY2018 May 31, 2017 $21.78B Jun 22, 2018
FY2018 May 31, 2016 $20.15B Jun 22, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2022 May 31, 2022 $0 Jun 21, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 4 Jun 18, 2025
FY2025 May 31, 2024 3 Jun 18, 2025
FY2025 May 31, 2023 3 Jun 18, 2025
FY2024 May 31, 2022 2 Jun 20, 2024
FY2023 May 31, 2021 4 Jun 20, 2023
FY2022 May 31, 2020 3 Jun 21, 2022
FY2021 May 31, 2019 3 Jun 21, 2021
FY2020 May 31, 2018 0 Jun 22, 2020
FY2019 May 31, 2017 2 Jun 21, 2019
FY2018 May 31, 2016 2 Jun 22, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 4 Jun 18, 2025
FY2025 May 31, 2024 3 Jun 18, 2025
FY2025 May 31, 2023 3 Jun 18, 2025
FY2024 May 31, 2022 2 Jun 20, 2024
FY2023 May 31, 2021 4 Jun 20, 2023
FY2022 May 31, 2020 3 Jun 21, 2022
FY2021 May 31, 2019 2 Jun 21, 2021
FY2020 May 31, 2018 0 Jun 22, 2020
FY2019 May 31, 2017 2 Jun 21, 2019
FY2018 May 31, 2016 2 Jun 22, 2018

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 2.81B Jun 18, 2025
FY2025 May 31, 2024 2.76B Jun 18, 2025
FY2024 May 31, 2023 2.71B Jun 20, 2024
FY2023 May 31, 2022 2.67B Jun 20, 2023
FY2022 May 31, 2021 2.81B Jun 21, 2022
FY2021 May 31, 2020 3.07B Jun 21, 2021
FY2020 May 31, 2019 3.36B Jun 22, 2020
FY2020 May 31, 2018 4.00B Jun 22, 2020
FY2020 May 31, 2017 4.14B Jun 22, 2020
FY2019 May 31, 2016 4.13B Jun 21, 2019

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $4.74B Jun 18, 2025
FY2025 May 31, 2024 $4.39B Jun 18, 2025
FY2025 May 31, 2023 $3.67B Jun 18, 2025
FY2024 May 31, 2022 $3.46B Jun 20, 2024
FY2023 May 31, 2021 $3.06B Jun 20, 2023
FY2022 May 31, 2020 $3.07B Jun 21, 2022
FY2021 May 31, 2019 $2.93B Jun 21, 2021
FY2020 May 31, 2018 $3.14B Jun 22, 2020
FY2019 May 31, 2017 $2.63B Jun 21, 2019
FY2018 May 31, 2016 $2.54B Jun 22, 2018